|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P416
|
Anti-tumor effects and immunological response following immune stimulating interstitial laser thermotherapy
|
Jakob Axelsson1, Cristina Pantaleone1
|
1Clinical Laserthermia Systems AB, Lund, Sweden
|
Inflammation | Tumor microenvironment | Tumor antigens | Solid tumors
|
|
P417
|
Post-marketing Safety of Checkpoint Inhibitors: Analysis of the FDA Adverse Event Reporting System
|
Rawad Elias1, Jennifer Rider2, Osama Rahma3
|
1Boston University Medical Center, Boston, MA, USA 2Boston University School of Public Health, Boston, MA, USA 3Dana-Farber Cancer Institute, Boston, MA, USA
|
Checkpoint blockade | Epidemiology | Immune toxicity
|
|
P418
|
Bromodomain and extraterminal region inhibitors slow melanoma tumor growth by altering the tumor microenvironment.
|
Dan A. Erkes1, Claudia Capparelli1, Shea A. Heilman1, Timothy J. Purwin1, Adam C. Berger1, Michael A. Davies2, Andrew E. Aplin1
|
1Thomas Jefferson University, philadephia, PA, USA 2MD Anderson Cancer Center, houston, TX, USA
|
T cell | Solid tumors | Tumor microenvironment | Checkpoint blockade | Inflammation | Tumor infiltrating lymphocytes (TILs)
|
|
P419
|
Tobacco use, awareness and cessation among Malayali tribes, Yelagiri Hills, Tamil nadu, India.
|
Delfin lovelina Francis1, Delfin lovelina Francis1, Delfin Lovelina Francis1
|
1Dr MGR Medical University, Chennai, India
|
Carcinogenesis
|
|
P420
|
Selection of First-in-Human Starting Dose of Anti-OX40 Agonist Monoclonal Antibody BMS-986178 Using a Pharmacokinetic/Pharmacodynamic-based Approach
|
Christine Huang1, Yan Feng1, Bryan Barnhart2, Michael Quigley1, John Huber1, Akintunde Bello1, Punit Marathe1, Praveen Aanur1, Timothy Reilly1, Zheng Yang1
|
1Bristol-Myers Squibb, Princeton, NJ, USA 2Bristol-Myers Squibb, Redwood City, CA, USA
|
Costimulation | Antibody
|
|
P421
|
Co-administration of dexamethasone with checkpoint blockade therapy increases survival in brain tumor model
|
Marsha-Kay Hutchinson1, Amber Giles1, Heather Sonnemann1, Jinkyu Jung1, Caitlin Reid1, Deric Park1, Mark Gilbert1
|
1National Institutes of Health, Bethesda, MD, USA
|
Costimulation | Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs) | Immune suppression | Antibody | Solid tumors | Inflammation
|
|
P422
|
Overall Survival and Treatment Patterns among Real-world Patients with Metastatic Non-Small Cell Lung Cancer Not Previously Treated with Systemic Therapy for Advanced Cancer
|
Jason C. Simeone1, Beth Nordstrom1, Ketan Patel2, Alyssa B. Klein3
|
1Evidera, Waltham, MA, USA 2AstraZeneca, Milton, United Kingdom 3AstraZeneca, Gaithersburg, MD, USA
|
Chemotherapy | Epidemiology | Checkpoint blockade | Solid tumors
|
|
P423
|
Overall Survival and Treatment Patterns among Real-World Patients with Stage IIIB Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy
|
Jason C. Simeone1, Beth Nordstrom1, Ketan Patel2, Alyssa B. Klein3
|
1Evidera, Waltham, MA, USA 2AstraZeneca, Milton, United Kingdom 3AstraZeneca, Gaithersburg, MD, USA
|
Chemotherapy | Epidemiology | Checkpoint blockade | Solid tumors
|
|
P424
|
Efficacy of Pembrolizumab (MK-3475) in Patients with Adrenocortical Carcinoma
|
Mohammed Amir Habra1, Matthew Campbell1, Camilo Jimenez1, Daniel Karp1, David Hong1, Vivek Subbiah1, Shubham Pant1, Jeane Painter1, Saria Khan1, Chantale Bernatchez1, Bettzy Stephen1, Anas Alshawa1, Coya Tapia1, Tito Mendoza1, Rivka Colen1, Kenneth Hess1, Funda Meric-Bernstam1, Aung Naing1
|
1MD Anderson Cancer Center, Houston, TX, USA
|
Clinical study | Clinical trial | Solid tumors
|
|
P425
|
Efficacy of Pembrolizumab in Patients with Cutaneous Squamous Cell Carcinoma
|
Renata Ferrarotto1, Bonnie Glisson1, George Blumenschein1, David Hong1, Sarina Piha-Paul1, Dipti Jain1, Anas Alshawa1, Jeane Painter1, Kenneth Hess1, Rivka Colen1, Chantale Bernatchez1, Charles Lu1, Bettzy Stephen1, Coya Tapia1, Tito Mendoza1, Funda Meric-Bernstam1, Aung Naing1
|
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Checkpoint blockade | Clinical study | Clinical trial | Solid tumors
|
|
P426
|
Antibody-drug conjugate induced cytotoxicity of tumor cell lines by targeting the SAS1B N-terminus
|
Arabinda Mandal1, Mriganka Mandal2, Walter Olson1, Jagathpala Shetty1, Kiley Knapp3, Eusebio Pires1, Todd Bauer1, Timothy Bullock4, John Herr4, Craig Slingluff1
|
1University of Virginia, Charlottesville, VA, USA 2Albemarle High School, Charlottesville, VA, USA 3University, Charlottesville, VA, USA 4University of Virginia.edu, Charlottesville, VA, USA
|
Antibody
|
|
P427
|
Democratizing Analysis of Cancer Data using the Cancer Genomics Cloud
|
Anurag Sethi1
|
1Seven Bridges Genomics, Inc, Boston, MA, USA
|
Gene expression | Tumor antigens
|
|
P428
|
PD-1 blockade activates CD4 T cells and the innate immune response for glioblastoma eradication
|
Sarah R. Klein1, Maria C. Speranza1, Prafulla C. Gokhale1, Margaret K. Wilkens1, Kristen L. Jones1, Apoorvi Chaudhri1, Paul T. Kirschmeier1, David A. Reardon1, Gordon J. Freeman1
|
1Dana-Farber Cancer Institute, Boston, MA, USA
|
Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Monocyte/Macrophage
|